US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Articles published by CareDx, Inc.

< Previous 1 2 3 4 5 Next >
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Second Quarter 2026 Financial Results
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Participate in Upcoming Investor Conferences
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Dismissal of 2021 Qui Tam Suit
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces First Quarter 2026 Financial Results
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From CareDx, Inc.
Via Business Wire
Tickers CDNA
News headline image
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response
From CareDx, Inc.
Via Business Wire
Tickers CDNA TXG
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
Tickers CDNA
< Previous 1 2 3 4 5 Next >